{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:35:22Z","timestamp":1780104922138,"version":"3.54.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MND"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.prrv.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T20:30:51Z","timestamp":1522960251000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["New and developing therapies in spinal muscular atrophy"],"prefix":"10.1016","volume":"28","author":[{"given":"Didu","family":"Kariyawasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.003_b0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.003_b0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.prrv.2018.03.003_b0025","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of Spinal Muscular Atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disord. doi:10.1016\/j.nmd.2017.11.004.","DOI":"10.1016\/j.nmd.2017.11.004"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.prrv.2018.03.003_b0035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0040","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.prrv.2018.03.003_b0045","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.003_b0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/156652409789105516","article-title":"Spinal muscular atrophy: molecular mechanisms","volume":"9","author":"Farrar","year":"2009","journal-title":"Curr Mol Med"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.003_b0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in Spinal Muscular Atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"issue":"15","key":"10.1016\/j.prrv.2018.03.003_b0065","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"18","key":"10.1016\/j.prrv.2018.03.003_b0070","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"10063","key":"10.1016\/j.prrv.2018.03.003_b0080","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.prrv.2018.03.003_b0085","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"issue":"16 Suppl.","key":"10.1016\/j.prrv.2018.03.003_b0090","article-title":"Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy (S46.003)","volume":"88","author":"De Vivo","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.prrv.2018.03.003_b0095","first-page":"S210","article-title":"P.379 \u2013 Infants and children with SMA treated with nusinersen in clinical trials: an integrated safety analysis","volume":"27","author":"Mercuri","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hache","year":"2016","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0105","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.prrv.2018.03.003_b0110","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.nmd.2017.06.415","article-title":"P.375 \u2013 Clinical studies of RG7916 in patients with spinal muscular atrophy: SUNFISH part 1 study update","volume":"27","author":"Mercuri","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.prrv.2018.03.003_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2017.06.411","article-title":"P.371 \u2013 Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results","volume":"27","author":"Charnas","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"10.1016\/j.prrv.2018.03.003_b0120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.prrv.2018.03.003_b0125","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","article-title":"Temporal requirement for high SMN expression in SMA mice","volume":"20","author":"Le","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.prrv.2018.03.003_b0135","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"16 Suppl.","key":"10.1016\/j.prrv.2018.03.003_b0140","article-title":"AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: experience with pre-existing anti-AAV9 antibody in the SMA1 population (S13.001)","volume":"88","author":"Sproule","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.003_b0145","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.prrv.2018.03.003_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","author":"Bevan","year":"2011","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0155","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.neuropharm.2012.02.013","article-title":"Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model","volume":"62","author":"Sunyach","year":"2012","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.003_b0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.003_b0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/hmg\/ddv629","article-title":"Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset","volume":"25","author":"Feng","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.prrv.2018.03.003_b0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.prrv.2018.03.003_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","author":"Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.prrv.2018.03.003_b0190","first-page":"11","article-title":"Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1","volume":"28","author":"Fitzgerald","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2018.03.003_b0200","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","author":"Burgart","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.003_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010167","article-title":"Investigation of new morpholino oligomers to increase survival motor neuron protein levels in spinal muscular atrophy","volume":"19","author":"Ramirez","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prrv.2018.03.003_b0210","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","author":"Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.prrv.2018.03.003_b0215","doi-asserted-by":"crossref","DOI":"10.1002\/mus.25164","article-title":"Rasch analysis of the pediatric evaluation of disability inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophy","author":"Pasternak","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.003_b0220","doi-asserted-by":"crossref","first-page":"e0172346","DOI":"10.1371\/journal.pone.0172346","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool","volume":"12","author":"Ramsey","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.003_b0225","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.prrv.2018.03.003_b0230","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.003_b0235","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mus.24670","article-title":"Spinal muscular atrophy functional composite score: a functional measure in spinal muscular atrophy","volume":"52","author":"Montes","year":"2015","journal-title":"Muscle Nerve"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218300484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218300484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T18:09:49Z","timestamp":1543601389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054218300484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":46,"alternative-id":["S1526054218300484"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2018.03.003","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and developing therapies in spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}